INVESTOR RELATIONS

Investor relations

NEWS

Lipum AB (publ) has terminated the liquidity provider assignment with Erik Penser Bank AB and has appointed Carnegie Investment Bank AB as new liquidity...
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced that the Board of Directors has appointed...
Lipum AB (publ) has published the interim report for period July to September for 2023. Below is a summary, a complete report (only in Swedish) is available...
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming...
Lipum AB (publ) has published the interim report for period January to June for 2023. Below is a summary, a complete report (only in Swedish) is available...
Lipum AB (publ) today reported that the scientific publication titled “Effects of bile salt-stimulated lipase on blood cells and associations with...
Lipum (publ) has entered a collaboration with researchers at the Karolinska Institute (KI), Division of Rheumatology at the Department of Medicine in Sweden...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
Lipum AB (publ) ("Lipum" or the "Company") announces that the subscription period in the Company’s capital raising begins today...

INVESTOR RELATIONS

Investor relations